---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059101"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:25:54.503213+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q1 revenue down 28% YoY, net loss $4.2M; apraglutide Phase III positive

## Summary
- Q1 total revenue $74.9M vs $104.1M YoY; GAAP net loss of $4.2M vs net income of $45.7M.
- LINZESS prescription demand grew 10% YoY; revenue impacted by gross-to-net change.
- Positive Phase III STARS trial of apraglutide in SBS-IF; NDA filing planned.
- Revised FY 2024 guidance due to LINZESS gross-to-net change estimate.
- Adjusted EBITDA fell to $12.8M from $60.4M YoY; non-GAAP net loss per share $(0.02).

## SEC filing metadata
- accession: 0001104659-24-059101
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465924059101/0001104659-24-059101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465924059101/tm2413858d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059101
- JSON: https://secwatch.observer/filing/0001104659-24-059101.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059101.txt

## Key facts
- Earnings Releases
  IRONWOOD PHARMACEUTICALS INC reported first quarter 2024 results: revenue $74,877, net income $(4,162), EPS $(0.03).
  - Period: first quarter 2024
  - Revenue: $74,877
  - Net income: $(4,162)
  - EPS: $(0.03)
  - Result: reported results
  source text: growth, and delivering sustained profits and cash flow.” First Quarter 2024 Financial Highlights 1 (in thousands, except for per share amounts) Q1 2024 Q1 2023 Total revenue 2 $ 74,877 $ 104,061 Total operating expenses 63,857 43,964 GAAP net income (loss) 2 (4,162 ) 45,714 GAAP net income (loss) – per share basic 2 (0.03 ) 0.30 GAAP net income (loss) – per
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465924059101/0001104659-24-059101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.